Quality & complianceOfficial

Denmark reports supply problems for Sedivet Vet. 10 mg/ml injection due to production issues

🇩🇰 DKMA · Wed 04 Nov 2026

DKMA says supply of Boehringer Ingelheim's romifidine veterinary injection is disrupted, with the disruption expected to last from early to mid-November 2026.

The Danish Medicines Agency (DKMA) published a notice on 4 November 2026 reporting current supply problems with Sedivet Vet. 10 mg/ml solution for injection. The product is marketed by Boehringer Ingelheim Animal Health Nordics A/S.

The notice gives the active substance as romifidine (as romifidine hydrochloride) and the ATC code as QN05CM93. It attributes the disruption to production problems.

DKMA gives the expected period of disruption as early November to mid-November 2026. The notice does not say when supply will be fully restored, and it does not name any alternative products.

The company field in the notice lists Boehringer Ingelheim Animal Health Denmark A/S, while the opening text refers to the Nordics entity. DKMA directs questions about the current status to the company.

What it means for your team

  • Veterinary supply and pharmacy teams in Denmark should ask the marketing authorisation holder directly for current stock and delivery status, as DKMA advises.
  • The stated window runs only to mid-November 2026, so it should be checked against actual availability rather than assumed.
  • The notice names no alternatives, so contingency planning for affected clinical needs falls to the users of the product.
  • Teams tracking Nordic shortages should note that the notice names two Boehringer Ingelheim entities (Nordics and Denmark).

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →